Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker. Weber – who was briefly chief operating officer of Takeda ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.

January 30, 2025 Drugmaker Takeda's CEO Weber to step down, raises profit forecast Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TAK-721 is one of 12 "Wave1" pipeline drug candidates that have been held up by Takeda as potential blockbuster products, because they are either best-in-class or first-in-class therapies. The ...

Visit a quote page and your recently viewed tickers will be displayed here.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

3382.T Seven & i Holdings Co., Ltd.

第9話 おいしい給食 アゲパンという名のスイーツ 2025年3月9日(日) 深夜0:00／KBS京都 失踪人捜索班消えた真実（2025 ...